Clinical consequences of generic substitution of lamotrigine for patients with epilepsy

Neurology

Volumn 72, Issue 21, 2009, Pages 1876-

  Boylan, Laura S ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG; LAMOTRIGINE; ANTICONVULSIVE AGENT; TRIAZINE DERIVATIVE;

BIOEQUIVALENCE; CANADA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENCY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; EPILEPSY; FOOD AND DRUG ADMINISTRATION; HUMAN; LETTER; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; DRUG INDUSTRY; HEALTH PERSONNEL ATTITUDE; HEALTH PROMOTION; NOTE; PATIENT SATISFACTION; PHARMACOKINETICS; TREATMENT OUTCOME;

ANTICONVULSANTS; ATTITUDE OF HEALTH PERSONNEL; DRUG INDUSTRY; DRUGS, GENERIC; EPILEPSY; HEALTH PROMOTION; HUMANS; PATIENT SATISFACTION; THERAPEUTIC EQUIVALENCY; TREATMENT OUTCOME; TRIAZINES;

EID: 67649204431     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/01.wnl.0000349653.30398.e8     Document Type: Letter

References (7)

1. J LeLorier MS Duh PE Paradis Clinical consequences of generic substitution of lamotrigine for patients with epilepsy Neurology 70 22 Pt 2 2008 2179 2186
2. Food and Drug Administration Available at: http://www.fda.gov/cder/index.html Accessed June 15, 2008.
3. GlaxoSmithKline. Available at: http://www.gsk.com/investors/presentations/q32004/q32004.pdf . Accessed August 8, 2008.
4. MC Meyer United States Food and Drug Administration requirements for approval of generic drug products J Clin Psychiatry 62 suppl 5 2001 4 9
5. GlaxoSmithKline. Available at: http://ctr.gsk.co.uk/Summary/lamotrigine/I_US51.pdf . Accessed August 8, 2008.
6. RL Waber B Shiv Z Carmon D Ariely Commercial features of placebo and therapeutic efficacy JAMA 299 2008 1016 1017
7. JW Miller GD Anderson MJ Doherty NP Poolos Position statement on the coverage of anticonvulsant drugs for the treatment of epilepsy: what's the problem with generic antiepileptic drugs? A call to action Neurology 69 2007 1806 1808 Letter.